Clavulanic acid

Jump to: navigation, search
Clavulanic acid
200px
Clinical data
Pregnancy
category
Routes of
administration
oral, IV
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability"well absorbed"
Metabolismhepatic (extensive)
Elimination half-life1 hour
Excretionrenal (30–40%)
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC8H9NO5
Molar mass199.16

WikiDoc Resources for Clavulanic acid

Articles

Most recent articles on Clavulanic acid

Most cited articles on Clavulanic acid

Review articles on Clavulanic acid

Articles on Clavulanic acid in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Clavulanic acid

Images of Clavulanic acid

Photos of Clavulanic acid

Podcasts & MP3s on Clavulanic acid

Videos on Clavulanic acid

Evidence Based Medicine

Cochrane Collaboration on Clavulanic acid

Bandolier on Clavulanic acid

TRIP on Clavulanic acid

Clinical Trials

Ongoing Trials on Clavulanic acid at Clinical Trials.gov

Trial results on Clavulanic acid

Clinical Trials on Clavulanic acid at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Clavulanic acid

NICE Guidance on Clavulanic acid

NHS PRODIGY Guidance

FDA on Clavulanic acid

CDC on Clavulanic acid

Books

Books on Clavulanic acid

News

Clavulanic acid in the news

Be alerted to news on Clavulanic acid

News trends on Clavulanic acid

Commentary

Blogs on Clavulanic acid

Definitions

Definitions of Clavulanic acid

Patient Resources / Community

Patient resources on Clavulanic acid

Discussion groups on Clavulanic acid

Patient Handouts on Clavulanic acid

Directions to Hospitals Treating Clavulanic acid

Risk calculators and risk factors for Clavulanic acid

Healthcare Provider Resources

Symptoms of Clavulanic acid

Causes & Risk Factors for Clavulanic acid

Diagnostic studies for Clavulanic acid

Treatment of Clavulanic acid

Continuing Medical Education (CME)

CME Programs on Clavulanic acid

International

Clavulanic acid en Espanol

Clavulanic acid en Francais

Business

Clavulanic acid in the Marketplace

Patents on Clavulanic acid

Experimental / Informatics

List of terms related to Clavulanic acid


Clavulanic acid (rINN) (IPA: [klævjuˌlænɪk ˈæsəd]) is a beta-lactamase inhibitor (GlaxoSmithKline formerly Beecham) sometimes combined with penicillin group antibiotics to overcome certain types of antibiotic resistance. Specifically, it is used to overcome resistance in bacteria that secrete beta-lactamase enzymes, which otherwise inactivate most penicillins. Most commonly, the potassium salt potassium clavulanate is combined with amoxicillin (co-amoxiclav [brand name Augmentin] or the veterinary formulation Synulox from Pfizer) or ticarcillin.

The name is derived from the Streptomyces clavuligerus microorganisms from which clavulanic acid is derived. Clavulanic acid is biosynthetically generated from the amino acid arginine and the sugar glyceraldehyde 3-phosphate.

Mechanism of action

Clavulanic acid has negligible intrinsic antimicrobial activity, despite sharing the β-lactam ring that is characteristic of beta-lactam antibiotics. However, the similarity in chemical structure allows the molecule to act as a competitive inhibitor of beta-lactamases secreted by certain bacteria to confer resistance to beta-lactam antibiotics. This inhibition restores the antimicrobial activity of beta-lactam antibiotics against β-lactamase-secreting resistant bacteria. Despite this, some bacterial strains have emerged that are resistant to even such combinations.

Adverse effects

The use of clavulanic acid with penicillins has been associated with an increased incidence of cholestatic jaundice and acute hepatitis during therapy or shortly after, particularly in men and those aged over 65 years. The associated jaundice is usually self-limiting and very rarely fatal. (Joint Formulary Committee, 2004)

The UK Committee on Safety of Medicines (CSM) recommends that treatments such as amoxicillin/clavulanic acid preparations should be reserved for bacterial infections likely to be caused by amoxicillin-resistant β-lactamase-producing strains, and that treatment should not normally exceed 14 days.

References

  • Joint Formulary Committee. British National Formulary, 47th edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004.

de:Clavulansäure nl:Clavulaanzuur sr:Клавуланска киселина



Linked-in.jpg